Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLU-VACS
NCT00133523Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2004
- Primary completion
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal), Fluzone Trivalent, influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated) in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2004; status: completed.
02
Drugs
influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal)Fluzone Trivalentinfluenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00133523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133523.